Gregory Kalemkerian, MD

Dr. Kalemkerian is a Professor in the Division of Hematology/Oncology at University of Michigan. He currently serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hematology/Oncology Fellowship Program. He cares for patients with lung cancer and other thoracic malignancies and his academic research interest is in clinical and translational trials for thoracic cancers.
Dr. Kalemkerian received his undergraduate and medical degrees from Northwestern University, followed by residency and chief residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at Johns Hopkins. He was a physician-scientist at Karmanos Cancer Institute from 1993-1999 and has been on faculty at the University of Michigan since 1999.
Dr. Kalemkerian’s honors include the receipt of the ASCO Excellence in Teaching Award, the University of Michigan Outstanding Clinician Award, and Fellow of ASCO recognition. He is a former chair of the NCCN Small Cell Lung Cancer Guideline Panel and the ASCO Scientific Program Committee’s Metastatic NSCLC and Professional Development Tracks. He has given over 200 invited lectures, authored more than 190 research articles, reviews, commentaries and book chapters, and edited two books on lung cancer
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MerckTopic:lung cancerDate added:06/15/2023Date updated:06/15/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BlueprintTopic:lung cancerDate added:06/15/2023Date updated:06/15/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:TakedaTopic:lung cancerDate added:06/15/2023Date updated:06/15/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:CullinanTopic:lung cancerDate added:06/15/2023Date updated:06/15/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:DaiichiTopic:lung cancerDate added:06/15/2023Date updated:06/15/2023